AKT1 and gastric cancer: Blocking the Akt signaling pathway through a clinically available Akt inhibitor, MK-2206, significantly enhanced radiosensitivity in radioresistant GC cell lines, which implies that Akt pathway could serve as a potential therapeutic target.